Cephalalgia : an international journal of headache
-
Randomized Controlled Trial Multicenter Study
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
The Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis assessed time of onset of onabotulinumtoxinA after the first treatment in total and responder populations and consistency weekly through five treatment cycles. ⋯ Treatment with onabotulinumtoxinA is associated with significant reductions in headache and migraine days/week at week 1, persisting after week 3, compared with placebo. Combined with earlier reports showing onabotulinumtoxinA treatment results in a persistent and progressive reduction in headache days over 56 weeks, it is suggested peak benefit may require multiple treatments.
-
Randomized Controlled Trial Multicenter Study
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Efficacy of galcanezumab in chronic migraine has been demonstrated in a pivotal Phase 3 study. Here, we assess efficacy in patients who have failed ≥2 and ≥1 prior migraine preventives for efficacy and/or safety reasons, and in those who never failed. ⋯ NCT02614261.